Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method

English version České info

Abstract:
While sorafenib (SFN) is the established worldwide standard therapeutic agent for advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) is also considered a favorable treatment for some advanced HCCs. This study aimed to evaluate each treatment and provide an optimal therapeutic choice for advanced HCCs. We analyzed 72 patients treated with SFN and 128 patients receiving HAIC. Both treatment groups were analyzed for prognostic and disease progression factors, and matched pair analysis was performed using the propensity score matching method. The preferable status of intrahepatic lesions, that is, no lesions or only a single (<3 cm) intrahepetic lesion, was positively associated with good prognosis and negatively associated with disease progression in the SFN group. Maximum tumor size (>5 cm) and low albumin (≤3.4 g/dL) were poor prognostic and disease progression factors in the HAIC group. Analysis of 53 patients selected from each of the SFN and HAIC groups based on the propensity score matching method showed no significant differences in survival or disease progression between the two matched subgroups. On the other hand, progression-free survival (PFS) in the HAIC-matched subgroup was significantly longer than in the SFN-matched subgroup, particularly in patients with portal vein invasion (PVI) and/or without extrahepatic spread (EHS). The treatment efficacy of HAIC is similar to that of SFN regarding survival and disease progression. Longer PFS might be expected for HAIC compared with SFN, particularly in patients with PVI and/or without EHS.

Keywords:
Disease progression; hepatic arterial infusion chemotherapy; hepatocellular carcinoma; prognosis; propensity score; sorafenib

Autoři: Kotaro Fukubayashi ¹; Motohiko Tanaka ¹; Kazuhiro Izumi ¹; Takehisa Watanabe ¹; Satomi Fujie ¹; Takeshi Kawasaki ¹; Yoko Yoshimaru ¹; Masakuni Tateyama ¹; Hiroko Setoyama ¹; Hideaki Naoe ¹; Ken Kikuchi ²; Yutaka Sasaki ^1,*
Působiště autorů: Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan ¹; Medical Quality Management Center, Kumamoto University Hospital, Kumamoto, Japan ²
Vyšlo v časopise: Cancer Medicine 2015; 4(8)
Kategorie: Original Research
prolekare.web.journal.doi_sk: https://doi.org/10.1002/cam4.476

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Souhrn

Keywords:
Disease progression; hepatic arterial infusion chemotherapy; hepatocellular carcinoma; prognosis; propensity score; sorafenib

Zdroje

1.Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Estimating the world cancer burden: global cancer statistics. CA Cancer J. Clin. 61:69–90.

2.Eguchi, S., T. Kanematsu, S. Arii, M. Okazaki, K. Okita, M. Omata, et al. 2008. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 143:469–475.

3.Tateishi, R., S. Shiina, M. Akahane, J. Sato, Y. Kondo, R. Masuzaki, et al. 2013. Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. PLoS ONE 8(4):e59040. doi:10.1371/journal.pone.0059040

4.Wilhelm, S. M., C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109.

5.Llovet, J. M., S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:378–390.

6.Cheng, A. L., Y. K. Kang, Z. Chen, C. J. Tsao, S. Qin, J. S. Kim, et al. 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.

7.Forner, A., M. E. Reiq, C. R. de Lope, and J. Bruix. 2010. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 30:61–74.

8.Xie, B., D. H. Wang, and S. J. Spechler. 2012. Sorafenib for the treatment of hepatocellular carcinoma: a systematic review. Dig. Dis. Sci. 57: 1122–1129.

9.Yamasaki, T., T. Kimura, F. Kurokawa, K. Aoyama, T. Ishikawa, K. Tajima, et al. 2005. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J. Gastroenterol. 40:70–78.

10.Ando, E., M. Tanaka, F. Yamashita, R. Kuromatsu, S. Yutani, K. Fukumori, et al. 2002. Hepatic infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: analysis of 48 cases.Cancer 95:588–595.

11.Nouso, K., K. Miyahara, D. Uchida, K. Kuwaki, N. Izumi, M. Omata, et al. 2013. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br. J. Cancer 109:1904–1907.

12.Nagano, H., A. Miyamoto, H. Wada, H. Ota, S. Marubashi, Y. Takeda, et al. 2007. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 110:2493–2501.

13.Obi, S., H. Yoshida, R. Toune, T. Unuma, M. Kanda, S. Sato, et al. 2006. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106:1990–1997.

14.Hiramine, Y., H. Uto, Y. Imamura, K. Tabu, Y. Baba, T. Hiwaki, et al. 2011. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: a comparative study. Exp. Ther. Med. 2:433–441.

15.Ikeda, M., S. Mitsunaga, S. Shimizu, I. Ohno, H. Takahashi, H. Okuyama, et al. 2014. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J. Gastroenterol. 49:932–940.

16.Rosenbaum, P. R., and D. B. Rubin. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70: 41–55.

17.Pattanayak, C. W., D. B. Rubin, and E. R. Zellb. 2011. Propensity score methods for creating covariate balance in observational studies. Rev. Esp. Cardiol. 64:897–903 (in Spanish).

18.Oken, M. M., R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis, E. T. McFadden, et al. 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:649–655.

19.Eggel, H.. 1901. Ueber das primäre Carcinoma der Leber. Beitr Z Path Anat u z allgem Pathol 30:506–604 (in German).

20.Kanai, T., S. Hirohashi, M. P. Upton, M. Noguchi, K. Kishi, M. Makuuchi, et al. 1987. Pathology of small hepatocellular carcinoma: a proposal for a new gross classification. Cancer 60:810–819.

21.Lencioni, R., and J. M. Llovet. 2010. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.Semin. Liver Dis. 30: 52–60.

22.Therasse, P., S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:205–216.

23.Marrero, J. A., M. Kudo, and J. P. Bronowicki. 2010. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 15(suppl 4):23–33.

24.Shirata, K., K. Matsuo, K. Muro, T. Doi, and A. Ohtsu. 2013. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. J. Cancer Res. Clin. Oncol. 139: 1383–1389.

25.Petrelli, F., and S. Barni. 2013. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann. Oncol. 24:186–192.

26.Broglio, K. R., and D. A. Berry. 2009. Detecting an overall survival benefit that is derived from progression-free survival. J. Natl. Cancer Inst. 101:1642–1649.

27.Reig, M., J. Rimola, F. Torres, A. Darnell, C. Rodriguez-Lope, A. Forner, et al. 2013. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology58:2023–2031.

28.Uchino, K., R. Tateishi, S. Shiina, M. Kanda, R. Masuzaki, Y. Kondo, et al. 2011. Hepatocellular carcinoma with extrahepatic metastasis. Cancer 117:4475–4483.

29.Ikai, I., M. Kudo, S. Arii, M. Omata, M. Kojiro, M. Sakamoto, et al. 2010. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol. Res. 40:1043–1059.

30.Longley, D. B., D. P. Harkin, and P. G. Johnston. 2003. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3:330–338.

31.Shirasaka, T., Y. Shimamoto, H. Ohshimo, H. Saito, and M. Fukushima. 1993. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother. Phamacol. 32:167–172.

32.Takaoka, A., S. Hayakawa, H. Yanai, D. Stoiber, H. Negishi, H. Kikuchi, et al. 2003. Integration of interferon-alpha/beta signally to P53 responses in tumor suppression and antiviral defense. Nature 424:516–523.

33.Monden, M., M. Sakon, Y. Sakata, Y. Ueda, and E. Hashimura. 2012. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: a multicenter, randomized, phase II study.Hepatol. Res. 42:150–165.